Schematic Visualization of In Vitro Digestion Process Steps and Pathways

To accurately represent biological breakdown stages, begin with three distinct phases: oral, gastric, and intestinal. Each phase requires precise markers for pH levels (6.8–7.0 for saliva, 1.5–3.0 for stomach acid, 6.5–7.4 for intestinal fluids), enzyme activity (α-amylase, pepsin, pancreatin), and incubation durations (5 min oral, 2 h gastric, 4 h intestinal). Use arrows to indicate fluid transfers–0.5 mL saliva to sample, 1:1 sample-to-gastric fluid ratio, sequential intestinal fluid additions at 1 h intervals.

Label critical control points: temperature (37°C ± 0.5°C), agitation speed (100 rpm), and sample homogeneity checks. Include inline symbols for dialysis membranes (1 kDa cutoff) if simulating absorption, with separate paths for retentate and permeate. For protein-rich substrates, add bifurcated branches showing protease-specific cleavage sites (e.g., trypsin/chymotrypsin targets).

Color-code segments: red for acidic conditions, blue for neutral/alkaline phases, and green for bile salt interactions (0–10 mM). Add a vertical timeline along the right margin, marking 15-minute increments. For validation, include measurement ports at each phase transition (HPLC, SDS-PAGE, or glucose/lipid assays) with dashed lines connecting to analytical outputs.

Prevent common errors by isolating the oral phase in a separate container symbol to avoid pH drift. Use triangular connectors for enzyme additions (each arrow labeled with μL/units). For lipophilic compounds, add a parallel sub-path showing micelles formation (Tween 20 or sodium taurocholate). Scale arrows proportionally to represent fluid volumes–never use uniform widths.

Visualizing Biochemical Breakdown: A Lab-Based Model

Construct your experimental workflow using three sequential phases to simulate human gastrointestinal processes: oral, gastric, and intestinal. Maintain precise pH control at 7.0 in the oral phase, 3.0 during gastric processing, and 7.0 in the intestinal segment. Use alpha-amylase (150 U/mL), pepsin (2000 U/mL), and pancreatin (100 U/mL trypsin activity) for enzymatic breakdown. Incubate samples at 37°C under constant agitation (150 rpm) to replicate peristaltic movement. Include bile salts (10 mM sodium taurocholate) in the intestinal phase to model micelle formation.

Critical Parameters for Reproducible Results

• Sample-to-fluid ratio: 1:4 (w/v) for accurate biomolecule interaction
• Enzyme inactivation: Heat treatment at 70°C for 10 minutes to halt reactions
• Buffer selection: Phosphate-buffered saline (PBS) for oral/intestinal stages, HCl-KCl buffer (pH 3.0) for gastric
• Time intervals: 2 min (oral), 2 h (gastric), 3 h (intestinal) to mirror physiological transit
• Sampling points: Collect aliquots at 15-min increments for kinetic analysis

1. Pre-heat all solutions to 37°C before mixing to avoid temperature shock
2. Verify enzyme activity using specific substrates (starch for amylase, hemoglobin for pepsin)
3. Use dialysis membranes (MWCO 1 kDa) for post-processing separation of low-molecular-weight products

Key Components of a Laboratory-Based Gastric Simulation System

Use simulated salivary fluid (SSF) with precise ionic composition: Na⁺ (14.4 mM), K⁺ (19.5 mM), Ca²⁺ (0.15 mM), Cl⁻ (25.2 mM), and HCO₃⁻ (5.0 mM). Adjust pH to 6.8 ± 0.2 using 1 M HCl or 1 M NaOH. Enzymatic activity requires 75 U/mL α-amylase (type VI-B from porcine pancreas) for starch breakdown. Maintain temperature at 37°C ± 1°C during incubation to replicate oral cavity conditions.

Gastric phase demands pepsin solution (3.2 g/L) in 0.1 M HCl, pH 1.5–2.0. Include 10 mM bile salts (taurocholic and glycocholic acids, 3:2 ratio) and 1 mM phospholipids (phosphatidylcholine) for lipid emulsification. Control chyme viscosity by adding 0.1–0.5% mucin (type II from porcine stomach) to mimic mucosal barriers. Rotate samples at 50 RPM to ensure homogeneous mixing without foaming.

Transition to intestinal simulation requires pancreatin (100 U/mL) and 10 mM bile extract in 0.1 M NaHCO₃, pH 7.0. Replace static models with dynamic bioreactors featuring peristaltic pumps (3–5 mL/min flow rate) to simulate intestinal transit. Use dialysis membranes (MWCO 1–3 kDa) to separate breakdown products from undigested solids. Monitor glucose release via enzymatic assays every 30 minutes to validate carbohydrate hydrolysis.

Electrolyte balance must match physiological ranges: Na⁺ (125–145 mM), K⁺ (4–6 mM), Ca²⁺ (1.2–1.5 mM), HPO₄²⁻ (3–5 mM). Add 1.5 mM MgSO₄ to prevent enzyme aggregation. Oxygenate solutions with 95% N₂/5% CO₂ gas mixtures to replicate anaerobic intestinal environments. Calibrate pH electrodes before each run using standardized buffers (pH 4.00 and 7.00).

Validate enzyme activity using substrate-specific controls: starch for amylase (DNS assay), bovine hemoglobin for pepsin (A₂₈₀), and tributyrin for lipase (titrimetric method). Sterilize reactants via 0.22 µm filtration to avoid microbial interference. Replace enzymes every 2 hours in prolonged experiments to compensate for degradation.

Sample collection points must correlate with physiological transit times: 0–2 min (oral), 30–60 min (gastric), 120–240 min (intestinal). Store aliquots at –20°C in polypropylene tubes to prevent analyte adsorption. Use LC-MS/MS for metabolite profiling, targeting amino acids, fatty acids, and short-chain sugars as biomarkers of simulation fidelity.

Step-by-Step Simulation of Oral, Gastric, and Intestinal Phases

Start by preparing a synthetic saliva solution with the following components per liter: 1.5 g NaHCO₃, 0.2 g K₂HPO₄, 0.8 g NaCl, 0.5 g α-amylase (EC 3.2.1.1), and 0.03 g mucin. Adjust pH to 6.8 ± 0.2 using 1 M HCl. Incubate samples (≤5 mm particle size) at 37°C for 2–5 minutes with a 1:1 (w/v) saliva-to-sample ratio, mixing at 50 rpm. Monitor starch degradation via iodine test every 30 seconds–discontinue when absorbance at 620 nm drops below 0.2.

Gastric Conversion Key Variables

• Prepare pepsin solution (0.02 g pepsin EC 3.4.23.1 per 100 mL) in 0.1 M HCl (pH 1.5 ± 0.1).
• Add 5 mM CaCl₂ to stabilize enzymes and prevent foaming.
• Maintain a 1:3 (w/v) sample-to-gastric fluid ratio for 2 hours at 37°C, stirring at 100 rpm via overhead mixer.
• Withdraw 5 mL aliquots every 15 minutes for protein hydrolysis analysis (TNBS assay or SDS-PAGE). Terminate at 90 minutes if protein bands below 10 kDa exceed 80% of total intensity.

Switch to intestinal conditions by neutralizing the gastric chyme with 1 M NaHCO₃ to pH 7.0. Add 0.4 g pancreatin (porcine, 4x USP) and 2.5 g bile salts per liter of simulated intestinal fluid (50 mM KH₂PO₄, 150 mM NaCl). Raise temperature to 39°C ± 0.5°C to mimic human core conditions. For lipid-rich samples, use a 2-stage approach: emulsify for 30 minutes at 200 rpm, then reduce to 50 rpm for 4–6 hours. Measure free fatty acids via GC-FID every 60 minutes–cessate when release rate plateaus (≤5% change over 3 consecutive readings). Track micronutrient bioaccessibility using ICP-MS for minerals (e.g., Zn, Fe) and HPLC for fat-soluble compounds (e.g., β-carotene, tocopherols).

Selecting Enzymes and Buffers for Precise Biochemical Simulation

Opt for pepsin with an activity range of 2,000–3,200 U/mg protein for gastric phase modeling, adjusting concentrations to 0.05–0.2% (w/v) based on target substrate complexity. Porcine pepsin (EC 3.4.23.1) remains the gold standard due to its consistent specificity and resistance to autolysis, unlike fungal or microbial alternatives. Verify enzyme purity via SDS-PAGE; contaminants above 5% skew hydrolytic patterns, particularly for proteins with disulfide bonds like β-lactoglobulin.

For intestinal replication, use pancreatin with defined protease (trypsin ≥ 10,000 BAEE U/mg), amylase (≥ 50,000 DU/mg), and lipase (≥ 20,000 FIP-U/g) ratios. Pancreatin from porcine pancreas (P7545, Sigma-Aldrich) at 0.1–0.4% (w/v) delivers reproducible cleavage, but requires bile salts (e.g., sodium taurocholate, 5–10 mM) to mimic emulsification. Replace pancreatin with individual enzymes (trypsin EC 3.4.21.4, chymotrypsin EC 3.4.21.1, elastase EC 3.4.21.36) only when simulating specific pathways, as synergy losses exceed 30% in multi-substrate systems.

Buffer Composition and pH Control

Gastric buffers demand HCl (0.1 M) for baseline pH 1.5–2.5, supplemented with 50–100 mM NaCl to replicate ionic strength. Avoid phosphate-containing buffers; they precipitate at low pH and interfere with enzyme stability. For intestinal phases, 50–100 mM KH₂PO₄/NaOH (pH 6.8–7.4) is optimal, but HEPES (20–50 mM) may be substituted for temperature-sensitive studies, despite its higher cost and lower buffering capacity below pH 7.0.

Include CaCl₂ (2–5 mM) in intestinal buffers to stabilize trypsin and amylase activity. Omit calcium if investigating mineral-sensitive substrates (e.g., phytates), but note that proteolytic efficiency drops by 20–40%. MgCl₂ or MnCl₂ (1–2 mM) can partially substitute for calcium-dependent enzymes, though they reduce chymotrypsin activity by 15%. For lipase-driven simulations, maintain bile salt concentrations (8–12 mM) and control osmolality (280–320 mOsm/kg) with NaCl to prevent micelle disruption.

Pre-treat enzymes with inhibitor assays if cross-contamination risks exist. Soybean trypsin inhibitor (1 mg/mL) confirms residual trypsin activity post-heat inactivation, while TLCK (tosyl lysyl chloromethyl ketone) selectively inhibits chymotrypsin without affecting elastase. Store enzymes at −80°C in single-use aliquots; repeated freeze-thaw cycles degrade pepsin by 0.5% per cycle and pancreatin by 1.2% per cycle, measured via azocasein or BAPNA assays.

Substrate-Specific Adjustments

For starch-rich matrices, amplify amylase concentrations to 0.5–1% (w/v) and extend incubation to 120 minutes; α-amylase alone yields incomplete saccharification (

After simulation, terminate reactions with 1 μM pepstatin A (pepsin) or 5 mM PMSF (serine proteases), ensuring immediate cooling to 4°C. Ultracentrifugation (100,000 × g, 60 min) separates soluble peptides from undigested residues; filter through 0.22 μm membranes to eliminate enzyme carryover before downstream LC-MS/MS or NMR analysis. Validate buffer-enzyme combinations via blank runs (substrate-free) to quantify background interference, which should not exceed 3% of target analyte signals.